- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Acrivon Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| Fr | H.C. Wainwright maintains Acrivon stock Buy rating, $19 target | 1 | Investing.com | ||
| Fr | Acrivon Therapeutics reports Q4 results | 5 | Seeking Alpha | ||
| Do | Acrivon Therapeutics, Inc: Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results | 53 | GlobeNewswire (Europe) | Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effects R&D event highlighted positive... ► Artikel lesen | |
| Do | Acrivon Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| Mi | Acrivon Therapeutics stock target cut to $19 by H.C. Wainwright | 7 | Investing.com | ||
| Mi | Cantor Fitzgerald maintains Overweight on Acrivon stock | 3 | Investing.com | ||
| ACRIVON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | Acrivon stops developing Lilly castoff for ovarian and bladder cancers to switch focus to endometrial | 8 | FierceBiotech | ||
| Mi | JMP maintains Acrivon stock with $17 target following update | 3 | Investing.com | ||
| Di | Acrivon Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Mo | Citizens JMP reiterates Acrivon stock with $17 target | 4 | Investing.com | ||
| 19.03. | Acrivon Therapeutics, Inc: Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates | 1 | GlobeNewswire (USA) | ||
| 14.03. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | Acrivon Therapeutics Stock Rises 14% On FDA Recognition For ACR-368 OncoSignature Assay | - | RTTNews | ||
| 05.02. | Acrivon Therapeutics gets FDA breakthrough device designation for its oncosignature assay for endometrial cancer | 2 | Seeking Alpha | ||
| 13.11.24 | Acrivon Therapeutics GAAP EPS of -$0.59 | 1 | Seeking Alpha | ||
| 13.11.24 | Acrivon Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11.24 | Acrivon Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.10.24 | Acrivon Therapeutics' SWOT analysis: promising oncology pipeline faces market hurdles | 1 | Investing.com | ||
| 16.10.24 | Acrivon Therapeutics, Inc: Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 140 | GlobeNewswire (Europe) | WATERTOWN, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon... ► Artikel lesen |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,90 | -1,36 % | Übernahmespekulationen und Kaufempfehlungen: Bayer, BioNTech, Evotec, BioNxt Solutions Aktie | Während bei Evotec derzeit die Übernahmespekulationen pausieren, nehmen sie bei BioNxt Solutions Fahrt auf. Das Unternehmen will in den kommenden 60 Tagen wichtige Meilensteine auf dem Weg zur Vermarktung... ► Artikel lesen | |
| CUREVAC | 2,788 | +0,50 % | EQS-News: CureVac erhält positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im Rechtsstreit mit BioNTech SE | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac erhält positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im Rechtsstreit mit BioNTech SE
27.03.2025... ► Artikel lesen | |
| AMGEN | 283,45 | +0,50 % | Which Dow Jones Stock Is Cheaper, Amgen or Merck? | ||
| NOVAVAX | 6,433 | -0,66 % | Moderna, Novavax Shares Are Sliding Wednesday: What's Going On? | ||
| BIOGEN | 127,55 | -0,08 % | Biogen Plans For State-of-the-Art Global Headquarters At Kendall Common, Set To Open In 2028 | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced Monday plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation... ► Artikel lesen | |
| MAINZ BIOMED | 5,695 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed rekrutiert ersten Patienten für seine klinische eAArly DETECT 2-Studie | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studie
Mainz Biomed rekrutiert ersten Patienten für seine klinische eAArly DETECT 2-Studie
27.03.2025 / 14:01... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,470 | -0,55 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity | 13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily
Results Expected in 2H25
SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,510 | +1,00 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with ... | CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,184 | -0,39 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,899 | +1,35 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,083 | +2,34 % | PacBio Appoints Jim Gibson As New CFO | WASHINGTON (dpa-AFX) - Life science technology company PacBio, Inc. (PACB) announced Thursday the appointment of Jim Gibson as the company's new Chief Financial Officer, effective as of his... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 65,66 | +1,02 % | How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion | ||
| EXELIXIS | 34,000 | +0,30 % | FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors | ||
| VAXART | 0,400 | +2,30 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on March 24, 2025, the independent members of the Board... ► Artikel lesen | |
| TEMPUS AI | 47,480 | -8,64 % | Why Tempus AI Inc. (TEM) Crashed On Wednesday? |
Das Unternehmen ACRIVON THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,250 (-10,00 %) liegt der Kurs bei 2,250 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACRIVON THERAPEUTICS INC finden Sie auf Wallstreet Online.
